Mechanism of Action
APJ Receptor Signaling
APJ (previously orphan GPCR) couples to Gi proteins, inhibiting adenylyl cyclase and reducing cAMP, with additional coupling to beta-arrestin pathways for receptor internalization. In cardiomyocytes, apelin/APJ signaling activates PI3K/Akt and ERK1/2 pathways, improving contractile function and promoting cardiomyocyte survival. In vascular smooth muscle, APJ activation causes vasodilation via NO release. Biased APJ agonists (preferentially Gi over beta-arrestin) may reduce receptor desensitization with chronic dosing.
Cardiovascular and Fluid Balance Effects
Apelin exerts positive inotropy (increasing cardiac contractility) while simultaneously causing vasodilation, a favorable hemodynamic profile for heart failure. Apelin counters vasopressin-mediated water retention by inhibiting V1b-mediated AVP release and directly opposing AQP2 upregulation in collecting ducts, promoting aquaresis. The apelin/APJ and AVP/V2R systems form a counterbalancing axis in fluid homeostasis.
Research Summary
Heart Failure
Phase 1/2IV apelin infusion in heart failure patients improves cardiac output and reduces systemic vascular resistance without tachycardia -- a hemodynamic profile superior to many existing agents. Phase 2 APLNR-HF trials with stable apelin analogs (CMF-019, MM07) are ongoing. APJ agonism for acute decompensated heart failure represents a potential new pharmacological mechanism distinct from catecholamines and PDE inhibitors.
Pulmonary Arterial Hypertension
Phase 2Apelin/APJ axis is reduced in PAH; APJ agonism dilates pulmonary vasculature and reduces right ventricular afterload in animal models. Combined with inhaled VIP or existing PAH drugs may offer additive benefit. Phase 2 trials of apelin analogs in PAH are ongoing. APJ receptors are highly expressed in pulmonary vascular smooth muscle, validating this target.
Metabolic Effects
Active ResearchApelin levels are low in insulin-resistant states and type 2 diabetes despite higher adiposity (apelin produced by adipocytes). Apelin improves insulin sensitivity in rodent models, promotes glucose uptake, and reduces hepatic glucose production. APJ agonism for metabolic syndrome is an emerging research direction.
Calculate your Apelin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Cardiac hemodynamics research | 30-100 nmol/kg IV bolus or 0.1-0.3 nmol/kg/min IV infusion | Per session | Intravenous |
Native apelin is rapidly degraded by ACE2 and other proteases; synthetic analogs with C-terminal modifications improve stability. Research peptide only; no approved therapeutic.
Interactions
Safety Profile
IV apelin infusion in healthy volunteers and heart failure patients has been well tolerated in Phase 1 studies. Transient flushing and mild hypotension at higher doses. No significant arrhythmias, hepatic, or renal adverse events. Short half-life and rapid enzymatic degradation provide an intrinsic safety margin. Stable analogs in Phase 2 trials have shown acceptable tolerability profiles. No long-term human safety data yet available.
References
- [1]Tatemoto K, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998;251(2):471-476.
- [2]Ashley EA, et al. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res. 2005;65(1):73-82.
- [3]Japp AG, et al. Vascular effects of apelin in vivo in man. J Am Coll Cardiol. 2008;52(11):908-913.